Industry view: Managing complex research and innovation portfolios in today s innovation environment. Thomas Görgen

Transcription

1 Industry view: Managing complex research and innovation portfolios in today s innovation environment Thomas Görgen

2 150 years Bayer Science For A Better Life Page 2 Taftie - Industry view Thomas Görgen

3 Bayer Science For A Better Life Employees Turnover 2014: 42.2 bn 302 Entities R&D 2014: 4.9 bn Subgroups: HealthCare Pharma Consumer Care Medical Care Animal Health MaterialScience Polycarbonates Polyurethanes Coatings, Adhesives and Specialties CropScience Crop Protection Seeds EnvironmentalScience Page 3 Taftie - Industry view Thomas Görgen

4 PUR Bayer Science For A Better Life Otto Bayer The inventor of polyurethanes: Dr. Otto Bayer Elastic and rigid materials Flexible Foams Rigid Foams Page 4 Taftie - Industry view Thomas Görgen

5 CAS PUR Bayer Science For A Better Life Otto Bayer The inventor of polyurethanes: Dr. Otto Bayer Elastic and rigid materials Flexible Foams Rigid Foams Kuno Wagner The inventor of aliphatic polyurethane coatings: Dr. Kuno Wagner Excellent weatherability, durability, gloss, efficiency in application Coatings for Automotive Coatings for Airplanes Page 5 Taftie - Industry view Thomas Görgen

6 PCS CAS PUR Bayer Science For A Better Life Otto Bayer The inventor of polyurethanes: Dr. Otto Bayer Elastic and rigid materials Flexible Foams Rigid Foams Coatings for Automotive Kuno Wagner Coatings for Airplanes Hermann Schnell The inventor of Polycarbonates: Dr. Hermann Schnell Crystal clear transparency, high temperature resistance, ductility Water-/Food Packaging Glazing Construction, Automotive Page 6 Taftie - Industry view Thomas Görgen

7 PCS CAS PUR Bayer Science For A Better Life Otto Bayer The inventor of polyurethanes: Dr. Otto Bayer Elastic and rigid materials Flexible Foams Rigid Foams Kuno Wagner The inventor of aliphatic polyurethane coatings: Dr. Kuno Wagner Excellent weatherability, durability, gloss, efficiency in application Coatings for Automotive Coatings for Airplanes Water-/Food Packaging Hermann Schnell Glazing Construction, Automotive Page 7 Taftie - Industry view Thomas Görgen

8 Pros & Cons of Public Funding Strengths Decrease innovation cost Partners help achieve own objectives Critical mass for technological breakthrough Dilute risk of s&t failure with partners HR Tool fellowships Political visibility & marketing tool Weaknesses Effort & costs of proposal preparation Delay by evaluation & negotiation processes Coordination of several partners Duties to report Cost statements Effort & costs of project management Long-term commitment to topics Opportunities Utilize external know-how Reduce time-to-market Business: Establish/care for relationship to customers and suppliers Develop new market with potential future customers Launch novel topics or improve their visibility Threats Share IP Concessions regarding market options Partially obligatory publication of results Rejection of proposals by funding bodies Page 8 Taftie - Industry view Thomas Görgen

9 Weakness: Complexity Issued by BMBF Simplified system is shown European system is not simpler Inhouse consulting is needed! Page 9 Taftie - Industry view Thomas Görgen

10 Horizon 2020 general remarks Up to higher TRL more expensive projects Higher funding rates more funds per project Competition even stronger Page 10 Taftie - Industry view Thomas Görgen

11 ETP SusChem Page 11 Taftie - Industry view Thomas Görgen

12 PPP SPIRE Sustainable Process Industry through Resource & Energy Efficiency Connect chemical industry with other process industries (cement, steel, glass, paper, ceramic ) Roadmapping - Initiation of topics on a long timescale Success rates 10-15% TRL up to 7 Usual H2020 rules apply Page 12 Taftie - Industry view Thomas Görgen

13 Innovative Medicines Initiative IMI: From IMI to IMI2 5 bn Euro for the future

14 JTI: Joining forces from public and private bodies The biggest public/private partnership in Life Science aiming to: Make drug R&D processes in Europe more innovative and efficient Enhance Europe s competitiveness Address key societal challenges Features IMI1 and IMI :1 funding, joint decision making, contributes in-kind All EU funds go to SMEs, academia, patient organisations and regulatory agencies Large pharmaceutical industry, represented by EFPIA Page 14 Taftie - Industry view Thomas Görgen

15 Working together beyond borders Multiple stakeholder teams with critical mass A Typical IMI Consortium, initiated by a group of pharma companies Pharma 1 Pharma 2 Pharma 3 EFPIA Pharma 4 Pharma 5 Pharma 6 ACADEMIA PATIENTS ORGANISATIONS SMALL AND MEDIUM-SIZED ENTERPRISES HOSPITALS REGULATORS Page 15 Taftie - Industry view Thomas Görgen

16 IMI projects Page 16 Taftie - Industry view Thomas Görgen

17 Project Example: Sharing compound collections Goal Generate novel leads for the development of innovative drugs from an exceptional collection of compounds. Objectives Create a highly diverse Joint European Compound Collection with ~ compounds from public and private institutions Establish a screening platform available to researchers in universities, SMEs and pharma industry Status / Achievements High quality compound collection (~ ) European Screening Center with state-of-the-art facilities 89 target programs running (public and private) with the option for generation of novel lead structures and tool compounds Total Budget: 196,539,059 Start of Project: 01/01/2013 Page 17 Taftie - Industry view Thomas Görgen

18 NATURE MEDICINE NEWS Example: 600 Mio. for Drug Safety Page 18 Taftie - Industry view Thomas Görgen

19 Evolution of IMI the road to IMI2 Make Drug R&D processes in Europe more efficient and effective and enhance Europe s competitiveness in the Pharma sector Idea generation Basic research and non-clinical testing Human testing Regulatory Approval HTA and Pharmacovigilance Daily Medical practice Primary focus of early IMI calls 2007 SRA Shift to also addressing challenges in in society and healthcare 2011 SRA IMI 2 includes real life medical practice 2013 SRA Page 19 Taftie - Industry view Thomas Görgen SRA Strategic Research Agenda

20 The Scientific Research Agenda of IMI2: Right prevention and treatment to right patient at the right time Page 20 Taftie - Industry view Thomas Görgen

21 IMI2 - Structure and Governance Broad Participation to be able to set ambitious goals Bigger budget: 3,45 Billion Euro, equally shared by EU and industry Not limited to EFPIA members: open for other industries / companies, which can contribute to the PPP goals (Healthcare IT, medical devices, ) SME Funding: Better conditions for medium sized SMEs than in IMI1: eligibility up to 500 mio Euro sales (companies according to EU rules to big for funding but too small to be able to afford non-funded participation) Standardized financial framework: 100 % Funding plus 25 % overhead matched by in kind contributions from EFPIA members Page Taftie - Industry view Thomas Görgen

22 From topic definition to project start Two-stage process Idea generation STAGE 1 STAGE 2 Negotiation phase EFPIA consortium Hospitals Academia Patients SMEs Regulators Applicant consortium EFPIA consortium Call Merger Negotiations Start Companies identify questions on which they want to work together Submission of Expressions of Interest by applicant consortia & Evaluation by independent experts Public and private partners develop a project together & IMI conducts peer review Signature of contracts Page 22 Taftie - Industry view Thomas Görgen

23 Summary Take Home Messages The novel PPP approach of IMI is a success story, showing its usefulness for addressing major, overarching challenges in R&D With IMI2 the partnership has been renewed until 2024 Focus: Stratified medicine and healthcare priorities Comprehensive: R&D, Regulatory, Market Access & Practice Multi-sector: beyond pharmaceutical sector room for win-win collaborations 187 allows own ruling ( i.e. new SME definition) Stage 1 evaluation should cover all 3 categories (S&T Excellence, Impact and Implementation) Page 23 Taftie - Industry view Thomas Görgen

24 EIT Climate: community Page 24 BTS TD Public Funding February 2015

25 EIT Climate: Community Page 25 Taftie - Industry view Thomas Görgen

26 EIT Climate: Budget 2015 Page 26 Taftie - Industry view Thomas Görgen

27 Refocus after four years of tremendous growth Page 27 Taftie - Industry view Thomas Görgen

28 Transforming Climate-KIC into a high impact organisation Page 28 Taftie - Industry view Thomas Görgen

29 Business Model Climate-KIC Page 29 Taftie - Industry view Thomas Görgen

30 Thank you!